Latest Updates in Breast Cancer
2026 Advances and Ongoing Challenges in HR-positive, HER2-Negative Metastatic Breast Cancer
Breast cancer is the most commonly diagnosed cancer among U.S. women, with HR-positive/HER2-negative disease predominating. Despite advances that have improved...
Maintenance Therapy Intensification with Palbociclib Improves PFS in HR-Positive, HER2-Positive Metastatic Breast Cancer
In the phase 3 PATINA trial, adding the CDK4/6 inhibitor palbociclib to maintenance HER2-targeted and endocrine therapy significantly prolonged progression-free...
FDA Approves Trastuzumab Deruxtecan (T-DXd) Plus Pertuzumab for First-Line HER2-Positive Metastatic Breast Cancer
The FDA has approved fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) plus pertuzumab for first-line treatment of unresectable or metastatic HER2-positive breast cancer....
Can Multimodal AI Be Trusted in the Clinic? New SABCS 2025 Data Support Its Role in Personalized Breast Cancer Care
At SABCS 2025, new data evaluated whether multimodal artificial intelligence (MMAI) can be trusted to support clinical decision-making in early-stage...
SABCS 2025: Redefining Endocrine-Based Care in HR+, HER2-Negative Breast Cancer Across Early and Metastatic Settings
Key data from SABCS 2025 highlight how endocrine-based, biology-driven strategies continue to reshape the management of ER-positive, HER2-negative breast cancer....
SABCS 2025: Transforming HER2+ Breast Cancer Care: Key Updates from HER2CLIMB-05, DESTINY, and PHILA Trials
This article reviews recent pivotal HER2+ breast cancer trials, highlighting oral TKIs, antibody-drug conjugates, and chemotherapy-sparing strategies. Key studies—including HER2CLIMB-05,...
Latest in HER2
Maintenance Therapy Intensification with Palbociclib Improves PFS in HR-Positive, HER2-Positive Metastatic Breast Cancer
In the phase 3 PATINA trial, adding the CDK4/6 inhibitor palbociclib to maintenance HER2-targeted and endocrine therapy significantly prolonged progression-free...
FDA Approves Trastuzumab Deruxtecan (T-DXd) Plus Pertuzumab for First-Line HER2-Positive Metastatic Breast Cancer
The FDA has approved fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) plus pertuzumab for first-line treatment of unresectable or metastatic HER2-positive breast cancer....
SABCS 2025: Transforming HER2+ Breast Cancer Care: Key Updates from HER2CLIMB-05, DESTINY, and PHILA Trials
This article reviews recent pivotal HER2+ breast cancer trials, highlighting oral TKIs, antibody-drug conjugates, and chemotherapy-sparing strategies. Key studies—including HER2CLIMB-05,...
TUKYSA Combination Improves Progression-Free Survival in First-Line HER2+ Metastatic Breast Cancer: HER2CLIMB-05 Phase 3 Results
TUKYSA combo improves PFS in first-line HER2+ metastatic breast cancer maintenance, the first update to treatment paradigm since 2012.
Verzenio Demonstrates Overall Survival Benefit in High-Risk Early Breast Cancer: Seven-Year monarchE Results
Two years of Verzenio plus endocrine therapy shows OS benefit in high-risk HR+, HER2- early breast cancer at seven-year follow-up.
FDA Grants Priority Review to Enhertu Plus Pertuzumab for First-Line HER2+ Metastatic Breast Cancer
FDA grants Priority Review for Enhertu plus pertuzumab in first-line HER2+ metastatic breast cancer, with decision expected April 2025.
Latest in HR
2026 Advances and Ongoing Challenges in HR-positive, HER2-Negative Metastatic Breast Cancer
Breast cancer is the most commonly diagnosed cancer among U.S. women, with HR-positive/HER2-negative disease predominating. Despite advances that have improved...
Maintenance Therapy Intensification with Palbociclib Improves PFS in HR-Positive, HER2-Positive Metastatic Breast Cancer
In the phase 3 PATINA trial, adding the CDK4/6 inhibitor palbociclib to maintenance HER2-targeted and endocrine therapy significantly prolonged progression-free...
Can Multimodal AI Be Trusted in the Clinic? New SABCS 2025 Data Support Its Role in Personalized Breast Cancer Care
At SABCS 2025, new data evaluated whether multimodal artificial intelligence (MMAI) can be trusted to support clinical decision-making in early-stage...
SABCS 2025: Redefining Endocrine-Based Care in HR+, HER2-Negative Breast Cancer Across Early and Metastatic Settings
Key data from SABCS 2025 highlight how endocrine-based, biology-driven strategies continue to reshape the management of ER-positive, HER2-negative breast cancer....
Verzenio Demonstrates Overall Survival Benefit in High-Risk Early Breast Cancer: Seven-Year monarchE Results
Two years of Verzenio plus endocrine therapy shows OS benefit in high-risk HR+, HER2- early breast cancer at seven-year follow-up.
Verzenio Achieves Overall Survival Milestone in Early Breast Cancer Competition”
Verzenio plus endocrine therapy offers statistically significant OS improvements over endocrine therapy alone in high-risk patients.
Latest in Triple Negative Breast Cancer (TNBC)
Datroway Achieves First OS Benefit in Immunotherapy-Ineligible Triple-Negative Breast Cancer
First cancer drug to show OS benefit vs chemotherapy for TNBC patients ineligible for immunotherapy in landmark phase 3 trial.
ASCENT-03: Trodelvy Plus Pembrolizumab Demonstrates Significant PFS Benefit in First-Line Metastatic Triple-Negative Breast Cancer
ASCENT-03 trial shows Trodelvy plus pembrolizumab significantly improved PFS vs chemo plus pembrolizumab in first-line mTNBC patients.
ENPP1 Inhibition Plus Radiation Prevents Breast Cancer Local Recurrence in Preclinical Models
ENPP1hi circulating tumor cells contribute to relapse by self-seeding mechanism requiring PMN-MDSC infiltration and NET formation.